Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28656077 | 0.77 | CYP19A1 (0.49) | CYP19A1CHRM3CHRM2LMNACYP2D6 | |
| SCHEMBL28559393 | 0.74 | CYP19A1 (0.44) | CYP19A1CHRM3 | |
| SCHEMBL1610847 | 0.74 | CYP19A1 (0.55) | CYP19A1CHRM3CHRM2LMNACYP2D6 | |
| SCHEMBL181269 | 0.73 | CHRM3 (0.45) | CYP19A1CHRM3CHRM2LMNACYP2D6 | |
| SCHEMBL28647858 | 0.72 | CHRM3 (0.46) | CYP19A1CHRM3CHRM2LMNACYP2D6 | |
| SCHEMBL27620093 | 0.72 | CHRM3 (0.56) | CYP19A1CHRM3CHRM2LMNACYP2D6 | |
| SCHEMBL31147060 | 0.72 | CYP19A1 (0.56) | CYP19A1CHRM3CHRM2LMNACYP2D6 | |
| SCHEMBL27884074 | 0.70 | MEN1 (0.51) | CHRM3CHRM2LMNACHRM1 | |
| SCHEMBL28658742 | 0.70 | CYP19A1 (0.42) | CYP19A1CHRM3CHRM2LMNACYP2D6 | |
| SCHEMBL28559325 | 0.70 | TAAR1 (0.44) | CYP19A1CHRM3LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |